LTRN today
$0.43-$0.03 (-5.82%)close Nov 13, 2026Trend
DailyDowntrend (confirmed)
4 hourStrong Bearish
1 hourExpanding
15 minStrong Bearish
5 minStrong Bearish
Daily trend turns up above $0.84
Key levels
Resistance$0.84
Resistance$0.50
Latest news & SEC filings
ProductStralight Therapeutics reports early-stage glioblastoma trial results for LP-184
ProductLantern Pharma wins Taiwan clearance to advance LP-300 study in never-smoker lung cancer
All LTRN news →About Lantern Pharma
Lantern Pharma is a clinical-stage oncology company that applies artificial intelligence to cancer drug development. Its pipeline features three experimental compounds, plus an early-stage antibody-drug conjugate program. The company pursues treatments for solid tumors and blood cancers, and runs a subsidiary dedicated to central nervous system and brain cancers.
Based on the company's 10-K filed Mar 30, 2026.
Nasdaq · Healthcare
Lantern Pharma Inc. (LTRN)
What Is the Price Target for LTRN?
SEPT Low Target
$0.00
SEPT Mid Target
$0.00
SEPT High Target
$0.00
Analyst Consensus
$0.00
Is LTRN a Buy or Sell Right Now?
Thesis
- •SEC filings signal active product innovation — 1 new product/expansion keywords detected in 10-K. R&D investment stable.
AI-Powered Trading Signals
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for LTRN.
Start Free Trial →Is LTRN Overvalued or Undervalued?
Valuation Verdict
N/A
Methods Used
N/A
Fair Value
$N/A
7
Moat Score
NONE
1/9
Piotroski Score
-15.6
Altman Z-Score
What Is Smart Money Doing with LTRN?
Insider Signal
NEUTRAL
2 buys / 0 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
N/A
Short Squeeze Risk
LOW
Signal: NEUTRAL
Track Smart Money Across 4,000+ Stocks
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →LTRN Growth Story
Revenue YoY
N/A%
3yr Revenue CAGR
N/A%
EPS Growth YoY
18.65%
FCF Growth YoY
12.0%
Revenue Trend
UNKNOWN
Dark Pool Trades for LTRN
PREVIEWSEPT Investing tracks real-time dark pool institutional trades for LTRN, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 17:15:14 | $0.44 | 6,800 | $$3K | BUY |
| 17:12:18 | $0.43 | 1,800 | $$774 | SELL |
| 17:07:05 | $0.43 | 1,345 | $$585 | BUY |
| 17:06:30 | $0.43 | 1,000 | $$435 | SELL |
| 16:45:07 | $0.43 | 2,000 | $$870 | SELL |
5 dark pool trades shown · $$6K preview volume
Real-time institutional flow, block trades, and net positioning
Full AI Research Report
SEPT's Trading AI has generated a free, downloadable PDF research report for Lantern Pharma Inc. (LTRN) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (1 articles analyzed), and SEC filing intelligence...
AI-Powered Trading Signals.
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →LTRN — frequently asked questions
What is LTRN stock price today?
Lantern Pharma Inc. (LTRN) is at $0.43, down 5.82% (-$0.03) at the Nov 13, 2026 close.
Why is LTRN stock moving today?
Latest LTRN news — Nov 10, 2026: Stralight Therapeutics reports early-stage glioblastoma trial results for LP-184 · Oct 7, 2026: Lantern Pharma wins Taiwan clearance to advance LP-300 study in never-smoker lung cancer
What do analysts rate LTRN?
Analyst ratings for LTRN: 2 Buy, 0 Hold, 0 Sell — consensus Strong Buy.
Did LTRN beat earnings?
LTRN last reported on Aug 14, 2026: EPS -$0.57 vs -$0.38 expected — a miss of 50.0%.
Does LTRN pay a dividend?
LTRN does not currently pay a dividend.
What are LTRN support and resistance levels?
Resistance: $0.50, $0.84, $1.07.
What are insiders doing with LTRN?
Insider activity: NEUTRAL, 2 buys and 0 sells in the last 90 days.
What is the latest news on LTRN?
Nov 10, 2026: Stralight Therapeutics reports early-stage glioblastoma trial results for LP-184 · Oct 7, 2026: Lantern Pharma wins Taiwan clearance to advance LP-300 study in never-smoker lung cancer